Bodycote gets twin private equity bids as buyers feast on London market
1 min read
The story
Bodycote, a FTSE 250 industrials group, has become the target of separate takeover approaches from private equity firms CVC and Veritas. The two offers value the company at approximately £1.8bn including debt, according to the Financial Times. The story frames this as part of a broader pattern of buyers targeting the London market, where valuations have often lagged those of US or European peers.
This matters for shareholders because a competitive bid situation — two credible PE sponsors circling the same asset — tends to put upward pressure on the eventual offer price relative to a single unsolicited approach. It also matters for the broader UK equities narrative, where persistent talk of a 'UK discount' has made London-listed industrials and mid-caps recurring targets for private capital looking to take companies private at valuations seen as cheap versus international comparables.
The second-order setup here is a classic takeover-arbitrage dynamic: with two bidders in play, there's a real possibility of a raised or competing formal offer, but also a real possibility that one or both approaches stall in due diligence or fail to secure board recommendation, especially if Bodycote's board judges £1.8bn as insufficient. Watch for confirmation of firm offer terms under UK Takeover Code 'put up or shut up' deadlines, any statement from Bodycote's board on valuation adequacy, and whether either PE firm formalizes an offer versus walking away, which would resolve the near-term uncertainty in either direction.
The case — both sides
0 of 1 names have verified EOD history. The basket chart is hidden rather than showing illustrative data.Missing: BOY.L
Having two separate PE bidders circling the same £1.8bn target increases the odds of a competitive process that results in a higher formal offer than either initial approach.
Dual unconfirmed approaches are not firm offers, and history shows early-stage PE interest in UK targets frequently fails to convert into a recommended deal, leaving the stock exposed if both bidders walk.
The house read
Two-sidedWith CVC and Veritas both circling Bodycote at roughly £1.8bn including debt, the market must decide whether a competing-bid dynamic pushes the eventual take-out price higher or whether one approach simply fades under due diligence.
Wrong ifEither CVC or Veritas could withdraw after due diligence, or Bodycote's board could reject both approaches as inadequate, causing shares to give back the takeover premium.
Published read · research, not advice